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Abstract
Various adaptive randomization procedures (adaptive designs) have been
proposed to clinical trials. This paper discusses several broad families of proce-
dures, such as the play-the-winner rule and Markov chain model, randomized
play-the-winner rule and urn models, drop-the-loser rule, doubly biased coin
adaptive design. Asymptotic theories are presented with several pivotal proofs.
The effect of delayed responses, the power and variability comparison of these
designs are also discussed.
1 Introduction.
As reported by the World Health Organization (Global Summary of the AIDS Epi-
demic, December 2006), the estimated number of people living with HIV is 39.5
million, causing 2.9 million deaths in 2006 and 13% are children under 15 years. The
alarming magnitude of AIDS epidemic and outbreaks of other fetal contagious dis-
eases such as SARS reveal how vulnerable our health care system is. In order to
search for more effective treatments, efficient clinical studies are urgently needed. In
clinical trials, the traditional balanced (or 50%-50%) treatment allocation rule been
challenged due to its possible unethical consequences. A frequently quoted clinical
trial is the study of the drug AZT in reducing risk of maternal-infract HIV transmis-
sion. While half of the pregnant women (239) are given the AZT drug, the remaining
mothers (238) receive the placebo when 50%-50% allocation scheme is used. Only 20
infants are HIV-positive in AZT group and 60 in the placebo group. (c.f., Connor et
al., New England J. Medicine, 1994). Balanced allocation resulted in many failures
in the placebo group.
Yao and Wei (1996) redesigned the AZT trial using an adaptive allocation rule, the
randomized play-the-wiener rule proposed by Wei and Durham (1978), and showed a
reduction of several treatment failures under adaptive allocation. Adaptive designs,
an important subdivision of experimental designs nowadays, are allocation rules in
which the probability a treatment assigned to the coming patient depends upon the
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results of the previous patients in the study. The basic goal is to skew allocation
probabilities to favor better treatment performance.
Early important work on adaptive designs was carried out by Thompson (1933)
and Robbins (1952). Since then, a steady stream of research (Zelen (1969), Wei and
Durham (1978), Wei (1979), Eisele and Woodroofe (1995), etc) in this area has gener-
ated various treatment allocation schemes for clinical trials. This paper provides the
recent theories of several broad families of designs. In Section 2, we state some limit
results on martingale, which are the basic tools to derive the asymptotic properties
of adaptive designs. In Section 3, we consider Zelen’s play-the-winner rule and its
generations by Lin, et al (2003). In Section 4, we derive the asymptotic properties of
the adaptive designs based on urn models, a large family of randomization procedures.
In Section 5, the drop-the-loser rule is introduced. In Section 6, an important family
of target-driven designs, the doubly adaptive biased coin designs, are discussed. In
Section 7, the effect of the delay of treatment results is discussed. In Section 8, we
compare the variabilities of different type of adaptive designs. The lower bound of
the asymptotic variability for a pre-specified allocation proportion is established, and
asymptotic best adaptive designs are provided. Finally, further discussion and future
topics are mentioned in Section 9. For the convenience of reading, we also give several
pivotal proofs. The principle ideas of deriving asymptotic properties can be found
from these proofs. Those who are not interested in the theoretical results can skip
these proofs and go quickly to the last two sections.
The following notations and definitions are introduced to describe the random-
ized treatment allocation schemes. Given a clinical trial with K treatments. Let
X1,X2, ... be the sequence of random treatment assignments. For the m-th sub-
ject, Xm = (Xm,1, . . . , Xm,K) represents the assignment of treatment such that if the
m-th subject is allocated to treatment k, then all elements in Xm are 0 except for
the k-th component, Xm,k, which is 1. Let Nn,k be the number of subjects assigned
to treatment k in the first n assignments and write Nn = (Nn,1, . . . , Nn,K). Then
Nn =
∑n
m=1Xm. We are interested in the statistical behavior of proportions Nn,k/n,
k = 1, . . . , K.
2 Preliminaries, limit theorems on martingales.
The martingale approach is the basic tool to investigate the asymptotic properties of
adaptive designs. In this section, we state some limit theorems on martingales. For
more results, one can refer to Hall and Heyde (1980) and Stout (1974) or other text
books. Let {Mn,Fn;n ≥ 1} be a real martingale sequence with ∆Mn = Mn −Mn−1
being it difference.
Theorem A (LLN) Let ηn > 0 be a sequence of random variables such ηn is Fn−1
measurable and ηn ր a.s., and p is a real number in (0, 2].
(a) Then with probability one,Mn/ηn → 0 on the event {ηn →∞,
∑∞
m=1 E
[|∆Mm|p|Fm−1]/ηpm <
∞}.
(b) If
∑n
m=1 E[(∆Mm)
2|Fm−1] ≤ ηn a.s., then with probability one Mn/ηn → 0 on
the event {ηn →∞}.
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Theorem B (LIL) Suppose supm E[|∆Mm|p] < ∞ for some p > 2, then Mn =
O(
√
n log log n) a.s.
Theorem C (CLT) Suppose there is a constant σ ≥ 0 such that∑nm=1 E[(∆Mm)2|Fm−1]/n P→
σ2. Further assume that the conditional Lindberg condition
1
n
n∑
m=1
E
[
(∆Mm)
2I{|∆Mm| ≥ ǫ
√
n|Fm−1
] P→ 0, ∀ǫ > 0
is satisfied. Then Mn/
√
n
D→ N(0, σ2). Further, M[nt]/
√
n
D→ σW (t) in D[0,∞),
where W (t) is a standard Brownian motion.
Theorem D (Skorokhod embedding theorem) In a possibly enlarged probability space
in which there is a standard motion B(t), we can redefine the martingale sequence
{Mn,Fn} without changing its distribution and define a non-decreasing sequence of
random variables {τn} such that τn is Fn measurable,Mn = B(τn) and E[∆τm|Fm−1] =
E[(∆Mm)
2|Fm−1] a.s., E[|∆τm|P |Fm−1] ≤ CpE[|∆Mm|2p|Fm−1] a.s. for p ≥ 1.
Theorem E (Strong approximation) Let {Mn,Fn;≥ 1} be a martingale sequence
in Rd space, Σn =
∑n
m=1 E[(∆Mm)
′∆Mm|Fm−1]. Suppose that there exists constants
0 < ǫ < 1 such that
∞∑
n=1
E
[‖∆Mn‖2I{‖∆Mn‖2 ≥ n1−ǫ∣∣Fn−1]/n1−ǫ <∞ a.s., (2.1)
and that T is a covariance matrix which is measurable with respect to Fk for some
k ≥ 0. Then for any δ > 0, (possibly in an enlarged probability space with {Mn} being
redefined) there exist κ > 0 and a d-dimensional standard BrowninW (t), independent
of T , such that
Sn −W (n)T 1/2 = O(n1/2−κ) +O(α1/2+δn ) a.s.
Here αn = maxm≤n ‖Σm −mT ‖.
If supn E‖∆Mn‖2+δ0 < ∞ for some δ0 > 0, then the condition (2.1) is satisfied.
The proofs of Theorem A (a), Theorem C and Theorem D can be found in Hall and
Heyde (1980). The proof of Theorem A (b) can be found in Stout (1974). Theorem B
can be proved by Theorem D and the LIL of a Brownian motion. The proof of Theorem
E is given in Zhang (2004). Also, Theorems A-C remain true for martingales in a Rd
space with some necessary notations changed.
3 Play-the-winner rule and Markov chain adaptive
design
Consider a two-arm clinical trial: two treatments (1 and 2) with dichotomous response
(success and failure). Patients (subjects) are recruited into the clinical trial sequen-
tially and respond immediately to treatments. Zelen (1969) proposed the following
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design, which is well known as the play-the-winner (PW) rule: A success on a partic-
ular treatment generates a future trial on the same treatment with a new patient. A
failure on a treatment generates a future trial on the alternate treatment. Let pi be
the success probability of a patient on the treatment i, qi = 1− pi, i = 1, 2. Then
Nn,1
n
P→ q2
q1 + q2
and
√
n(
Nn,1
n
− q2
q1 + q2
)
D→ N(0, σ2PW ),
where σ2PW = q1q2(p1 + p2)/(q1 + q2)
3. Notice that q2/(q1 + q2) > 1/2 if p1 > p2. So,
if treatment 1 is ”doing better”, the PW rule favors treatment 1.
Lin, Bai, Chen and Hu (2003) extended the PW rule to a general Markov Chain
adaptive design. Suppose that at the stage m, the treatment 1 is assigned to the mth
patient. Then the (m+ 1)th patient will be assigned either treatment 1 or treatment
2 according certain probabilities, which depend on the response of the mth patient.
Let αs be the probability of assigning the (m+1)th patient to treatment 1, when the
response of the mth patient to treatment 1 is “success”, and let αf be the probability
of assigning the (m+1)th patient to treatment 1, when the response of themth patient
to treatment 1 is “failure”. Similarly define βs and βf with treatment 2 instead of
treatment 1 in the definitions of αs and αf . When αs = 1, αf = 0, βs = 1, βf = 0,
we get Zelen’s PW rule. A clinical application disadvantage of the PW rule is that
it is fully deterministic, i.e., when the previous results are known, the assignment of
the next subject is fully determined. The Markov chain adaptive design is not fully
deterministic except when the parameter αs, αf , βs and βf take extreme values 0 and
1. When taking αs = αf = βs = βf = 1/2, we get the fully randomization procedure
which allocates patients to each treatment with a probability 1/2. The more are
the parameters near extreme values, the more is the procedure being deterministic.
When αs < αf and βs < βf , the Markov chain adaptive design is less ethical than the
balanced allocation (c.f., Equation (3.1)). The parameters αs, αf , βs and βf can be
chosen to reflect the trade-off between the degree of randomness and ethic.
Let p1(m) = P{success |Xm,1 = 1} and p2(m) = P{success |Xm,1 = 0} and
αm = p1(m)αs + (1 − p1(m))αf , βm = p2(m)βs + (1 − p2(m))βf . Then {Xm,1} is a
Markov chain with the transition probability matrix
Pm =
(
αm 1− αm
1− βm βm
)
.
When p1(m) = p1 and p2(m) = p2 for all m, αn ≡ α, βn ≡ β, and {Xm,1} is
a homogeneous Markov chain with a stationary distribution (µ, 1 − µ), where µ =
(1− β)/(2− α − β). Following from the central limit theorem for Markov chains we
have that
Nn,1
n
P→ µ and √n(Nn,1
n
− µ) D→ N(0, σ2) (3.1)
where
σ2 = Varµ{X1,1}+ 2
∞∑
j=2
Covµ{X1,1, Xj,1} = (1− α)(1− β)(α + β)
(2− α− β)3 .
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For non-homogeneous case, Lin, Bai, Chen and Hu ( 2003) proved (3.1) under the
condition that ∞∑
m=1
|p1(m)− p1|+ |p2(m)− p2|√
m
<∞.
Lin, Zhang, Cheung and Chan (2005) established the strong approximation for
Nn,1, from which (3.1) follows immediately.
Theorem 3.1 In a possibly enlarged probability space, we can redefine the sequence
{Nn,1} without changing its distribution, such that
Nn,1 − nµ − σW (n) = O((n log logn)1/4(log n)1/2) +O(∆n) a.s.,
where {W (t)} is a standard Brownian motion and ∆n =
∑n
m=1(|αm−α|+ |βm− β|).
Proof. Write ∆mm = Xm,1 − E[Xm,1|Fm−1], where Fm−1 is the history sigma field
generated by Xm,1, . . . , Xm−1,1. Then Xm = ∆mm+E[Xm,1|Fm−1] = ∆mm+1−βm−
(1−αm−βm)Xm−1,1. It follows thatNn,1 = mn+1−β−(1−α−β)Nn−1,1+O(∆n)+O(1).
So,
Nn,1 = nµ+mn/(2− α− β) +O(∆n).
For the martingale mn, we have E[(∆mm)
2|Fm−1] = (1−βm)βm+(αm−βm)(1−αm−
βm)Xm−1,1 and |∆mm| ≤ 1. It follows that
n∑
m=1
E[(∆mm)
2|Fm−1]
=n(1 − β)β + (α− β)(1− α− β)Nn−1,1 +O(∆n)
=n(1 − β)β + n(α− β)(1− α− β)µ+ (α− β)(1− α− β)
2− α− β mn +O(∆n)
=n
(1− α)(1− β)(α+ β)
2− α− β +O(∆n) +O(
√
n log log n)
=:nσ2M +O(∆n) +O(
√
n log log n) a.s.
due to the LIL (Theorem B). Applying the Skorokhod embedding theorem (Theo-
rem D), we can write mm = B(τm). Notice
∑n
m=1
(
∆τm − E[∆τm|Fm−1]) is also a
martingale sequence. By the LIL, we conclude that
τn =
n∑
m=1
E[∆τm|Fm−1] +O(
√
n log log n)
=
n∑
m=1
E[(∆mm)
2|Fm−1] +O(
√
n log log n)
=nσ2M +O(∆n) +O(
√
n log log n) a.s.
It follows that
mn =B(τn) = B(nσ
2
M ) +O
(√
(∆n +
√
n log logn) logn
)
=B(nσ2M) +O(∆n) +O((n log logn)
1/4(log n)1/2) a.s.
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by the sample properties of a Brownian motion (c.f., Cso¨rgo˝ and Re´vs´z (1980)). The
proof is now completed by letting W (t) = B(tσ2M )/σM and noticing that σ
2
M/(2−α−
β)2 = σ2. ✷.
For the multi-treatment case, we let pi(m) = P(success |Xm,i = 1}. Assume the
transition probability matrix of the Markov chain {Xn} is Hn = {Hij(n)} which is
a function of pi(n), i = 1, . . . , K, i.e, E[Xn+1|Xn] = XnHn. By using Theorem E
instead of the Skorokhod embedding theorem, Zhang (2004) showed that Nn can be
approximated by a multi-dimensional Browian motion:
Nn − nv −W (n)Σ = o(n1/2−κ) +O
( n∑
k=1
‖Hk −H‖
)
a.s.,
where κ > 0, v = (v1, · · · , vK) is the left eigenvector corresponding to the largest
eigenvalue ofH with v1+. . .+vK = 1, {W (t)} is aK-dimensional standard Brownian
motion. In particular, we have asymptotic normality, if
n∑
k=1
‖Hk −H‖ = o(n1/2). (3.2)
Zhang (2006) studied a kind of non-humongous Markov chain designs, in which Hn
is a function of an estimated unknown parameters θ̂. In this case the condition (3.2)
is not satisfied.
4 Randomized play-the-winner rule and urn mod-
els
To overcome the drawback that the PW rule is fully deterministic, Wei and Durham
(1978) introduced the following randomized play-the-winner (RPW) rule: We start
with (α, β) balls (type 1 and 2 respectively) in the urn. If a type k ball is drawn, a
patient is assigned to the treatment k, k = 1, 2. The ball is replaced and the patient’s
response is observed. A success on the treatment 1 or a failure on the treatment 2
generates a type 1 ball in the urn; A success on the treatment 2 or a failure on the
treatment 1 generates a type 2 ball in the urn. Let Yn,1 (Yn,2) be number of balls of
type 1 (2) after n stage. From the results of Athreya and Karlin (1968), we have
Yn,1
Yn,1 + Yn,2
→ q2
q1 + q2
a.s. and
Nn,1
n
→ q2
q1 + q2
a.s..
The limiting proportion is the same as that of the PW rule. We refer to it as urn
proportion. When p1 + p2 < 1.5 (or q1 + q2 > 0.5), we have the following asymptotic
normality:
√
n(
Yn,1
Yn,1 + Yn,2
− q2
q1 + q2
)
D→ N(0, q1q2
(2(q1 + q2)− 1)(q1 + q2)2
)
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and
√
n(Nn,1/n− q2/(q1 + q2)) D→ N(0, σ2RPW ), where
σ2RPW =
q1q2[5− 2(q1 + q2)]
[2(q1 + q2)− 1](q1 + q2)2 . (4.1)
The asymptotic normality was first given in Smythe and Rosenberger (1995). When
q1+q2 < 0.5, the limiting distributions of both the urn composition and the allocation
proportion are unknown. The RPW rule has the same limiting allocation proportion
as the PW rule. But the asymptotic variability is much larger.
As multi-treatment extensions of the RPW rule, one large family of randomized
adaptive designs can be developed from the generalized Polya urn (GPU) model. Urn
models have also long been recognized as valuable mathematical apparatus in many
areas including physical science, biological science, engineering, information science,
the study of economic behaviors, etc.
Consider an urn containing balls of K types. Initially, the urn contains Y0 =
(Y0,1, · · · , Y0,K) balls, where Y0,k denotes the number of balls of type k, k = 1, · · · , K.
A ball is drawn at random. Its type is observed and the ball is then replaced. At the
mth stage, following a type k drawn, Dkj(m) (≥ 0) balls of type j, for j = 1, · · · , K,
are added to the urn. Dij(m) is a random function of the response ξm,k of the m-th
subject on treatment k. The expectation of the total numbers of balls added in each
stage is assumed to be the same (say γ), so
K∑
j=1
E{Dkj(m)|Fm−1} = γ, k, j = 1, · · · , K,m = 1, 2, · · · ,
where Fm−1 is the history sigma field. Without loss generality, we can assume γ = 1.
Let Hm be the matrix comprising element {hij(m) = E[Dkj(m)|Fm−1]} and Dm =
{Dkj(m)}. We refer to Dm as the adding rules and Hm as the design matrices. If
Dm, m = 1, 2, . . . , are i.i.d., then Hm =H for all n. In this case the model is said to
be homogenous. In general, it is assumed that Hm →H . Let Yn = (Yn,1, · · · , Yn,K),
where Yn,k represents the number of balls in the urn of type k after nth stage. And
let v = (v1, · · · , vK) be the left eigenvector corresponding to the largest eigenvalue of
H with v1+ . . .+vK = 1. Then vk is just the limiting proportion of both the patients
assigned to treatment k and the type k balls in the urn. Bai, Hu and Zhang (2002), Hu
and Zhang (2001) obtained the asymptotic properties via the strong approximation.
Theorem 4.1 Suppose that {Dm} is sequence of i.i.d. random matrices with supm E‖Dm‖2+δ <
∞. Let λ1 = γ = 1, λ2, . . . , λK be the eigenvalues ofH, and λ = max{Re(λ2), . . . , Re(λK)}.
If λ < 1, then
Nn,i
n
→ vi a.s. and Yn,i∑K
j=1 Ynj
→ vi a.s. (4.2)
If λ < 1/2, then
√
n(
Yn
n
− v) D→ N(0,Σ) and √n(Nn
n
− v) D→ N(0,Σ∗). (4.3)
7
Proof. Write 1 = (1, . . . , 1), |Yn| =
∑K
k=1 Ynk, H˜ =H−1′v,Mn =
∑N
m=1Xm(Dm−
H), mm =
∑n
m=1(Xm − E[Xm|Fm−1]). Then H1′ = 1′, mn1′ = 0, and the eigen-
values of H˜ are 0, λ2, . . . , λK . We have the following lemma on matrices, the proof of
which can be founded in Hu and Zhang (2004a).
Lemma 4.1 If ∆Qn = ∆Pn +Qn−1H˜/(n− 1), n ≥ 2, then
‖Qn‖ = O(‖Pn‖) +
n∑
m=1
O(‖Pm‖)
m
(
n/m)λ logν−1(n/m),
where ν is the degree of the second largest eigenvalue of H.
We prove (4.3) only. Notice
∆(Yn − nv) =XnDn − v = ∆Mn +∆mnH + Yn−1|Yn−1|H − v
=
Yn−1 − (n− 1)v
n− 1 H˜ +∆Mn +∆mnH˜
+
(
1− |Yn−1|
n− 1
)(
Yn−1
|Yn−1| − v
)
H˜ . (4.4)
Multiplying 1′ yields |Yn| −n = ∆Mn1′+ |Y0| = O(
√
n log log n) a.s. due to the LIL
(Theorem B). It follows that
Mn +mnH +
n−1∑
m=1
(
1− |Ym|
m
)(
Ym
|Ym| − v
)
H˜ = O(
√
n log log n) a.s.
By applying Lemma 4.1 and noticing λ < 1/2, we obtain Yn−nv = O(
√
n log logn) a.s.
Write D
(k)
1 = (Dk1, . . . , DkK), Σ1 = diag(v)− v′v and Σ2 =
∑K
k=1 vkVar{D(k)1 }. For
the martingale (Mn,mn), we have supn E‖∆Mn‖2+δ <∞, ‖∆mn‖ ≤ K, E[(∆Mn)′∆mn|Fm−1] =
0 and
n∑
m=1
E
[
(∆mm)
′∆mm|Fm−1
]
=
n∑
m=1
[diag
( Ym
|Ym|
)− ( Ym|Ym|
)′ Ym
|Ym| ]
=nΣ1 +O(
√
n log logn) a.s.,
n∑
m=1
E
[
(∆Mm)
′∆Mm|Fm−1
]
=
n∑
m=1
K∑
k=1
Var{D(k)1 }Ymk/|Ym|
=nΣ2 +O(
√
n log logn) a.s.
By the strong approximation (Theorem E), there are two independent d-dimensional
standard Brownian motionsW1(t) and W2(t) such that for some κ > 0,
mn =W1(n)Σ
1/2
1 + o(n
1/2−κ) a.s., Mn =W2(n)Σ
1/2
2 + o(n
1/2−κ) a.s. (4.5)
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Without loss generality, we assume 1/2− κ > λ and 1/2− κ > 1/4. Let Gi(t) be the
solution of the equation
Gi(t) =
∫ t
0
Gi(x)
x
H˜dx+Wi(t)Σ
1/2
i , Gi(0) = 0, (4.6)
i = 1, 2. Notice {[Wi(T (· + s)) −Wi(T ·)]/
√
T} D= {Wi(·)}. It can be checked that
Gi(t) is a Gaussian process with stationary increments and Var{Gi(t)} = tVar{Gi(1)},
and ∫ n
0
Gi(x)
x
dx =
n−1∑
m=1
Gi(m)
m
+O((logn)3/2) a.s. (4.7)
Combing (4.4)–(4.7) yields
Yn − nv −G2(n)−G1(n)H˜ =
n−1∑
m=1
Ym −mv −G2(m)−G1(m)H˜
m
H˜ + Pn,
where
Pn = O((logn)
3/2) + o(n1/2−κ) +
n−1∑
m=1
(
1− |Ym|
m
)(
Ym
|Ym| − v
)
H˜
=O((logn)3/2) + o(n1/2−κ) +
n−1∑
m=1
(√
(log logm)/m
)2
= o(n1/2−κ) a.s.
Now, by applying Lemma 4.1 we conclude that
Yn − nv = G2(n) +G1(n)H˜ + o(n1/2−κ) a.s.
Finally,
Nn − nv =mn +
n−1∑
m=0
Ym
|Ym| − nv =mn +
n−1∑
m=0
(
Ym
|Ym| − v
)
(I − 1′v)
=mn +
n−1∑
m=1
Ym −mv
m
(I − 1′v)
+
n−1∑
m=1
(
1− |Ym|
m
)(
Ym
|Ym| − v
)
(I − 1′v) +O(1)
=W1(n) +
n−1∑
m=1
G2(m) +G1(m)H˜
m
(I − 1′v) + o(n1/2−κ)
=W1(n) +
∫ n
0
G2(x) +G1(x)H˜
x
dx(I − 1′v) + o(n1/2−κ)
=G1(n) +
∫ n
0
G2(x)
x
dx(I − 1′v) + o(n1/2−κ) a.s.
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(4.3) is now proved, where Σ and Σ∗ are the variance-covariance matrices of normal
random variables G2(1)+G1(1)H˜ and G1(1)+
∫ 1
0
G2(x)/x dx (I−1′v), respectively.
For the details of specifying and estimating the variance-covariance matrices, one can
refer to Bai and Hu (2005), Hu and Zhang (2004b), Zhang, Hu and Cheung (2006).
✷
The interested one can check that for the RPW rule, the equation (4.6) reduces to
Gi,1(t) = λ
∫ t
0
Gi,1(x)
x
dx+ σiWi(t), Gi,1(0) = 0,
Gi,2(t) = −Gi,1(t), and the solution is Gi,1 = σitλ
∫ t
0
x−λdWi(x), i = 1, 2, where λ =
1−q1−q2, σ21 = v1v2 = q1q2/(q1+q2)2 and σ22 = v1p1q1+v2p2q2 = q1q2(p1+p2)/(q1+q2).
When only the second moment of Dm is assumed to be finite, we can show (4.3)
with a similar argument by applying the weak convergence of martingales (Theorem
C) instead of the strong approximation. For details one can refer to Hu and Zhang
(2001). Janson (2004) studied the urn models by embedding them to continuous
branching processes and established the asymptotic normality in a different way.
Example 4.1 As a multi-treatment extension of the RPW rule, Wei (1979) proposed
a GUP to allocate subjects, in which the urn is updated in the following way: at the nth
stage, if a subject is assigned to treatment k and cured, then a type k ball is added to the
urn, otherwise, if treatment k for a subject fails, then 1
K−1 balls are added to the urn
for each of the other K−1 treatments. In this urn model, H = {hkj, k, j = 1, . . . , k},
where hkk = pk and hkj = qk/(K − 1) (j 6= k), and pk is the successful probability of
treatment k, qk = 1− pk. So vk = (1/qK)/
∑K
j=1(1/qj).
For the non-homogenous case, Bai and Hu (2005) obtained (4.3) under the condi-
tion that ∞∑
m=1
‖Hm −H‖√
m
<∞ a.s. (4.8)
This condition can be weakened to
∑n
m=1 ‖Hm −H‖ = o(
√
n) a.s. by use the argu-
ment in the above proof. An applicable class of non-homogenous urn models is the
sequential estimation-adjusted urn (SEU) model, in which the urn is updated accord-
ing to the current response and the current estimate of an unknown parameter, and so
Hm =H(θ̂m) is a function of the estimator. In this case, the fastest convergence rate
of Hm is OP (
√
m) and the condition (4.8) is not satisfied. Zhang, Hu and Cheung
(2006) established the asymptotic properties of SEU models.
Example 4.2 Bai, Hu and Shen (2002) proposed a GUP to allocate subjects, in which
the urn is updated in the following way: at the mth stage, if a subject is assigned
to treatment k and cured, then a type k ball is added to the urn. If a failure, then
bpm−1,jP
i6=k bpm−1,i balls of each type j 6= k are added. Where p̂m−1,j = (Sm−1,i+1)/(Nm−1,j+1),
and Sm−1,j is the number of successes of treatment j in previous m − 1 stages. This
model is a SEU model with H(x) = {hij(x); i, j = 1, . . . , K}, where hkk(x) = pk and
hkj(x) = qkxj/
∑
i 6=k xi (j 6= k).
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More examples and applications of SEU models can be found in Zhang, Hu and
Chueng (2006), in which how to defined a SEU model by using the information of
distribution parameters to target a pre-specified limiting allocation proportion is dis-
cussed in details.
5 Drop-the-loser rule
The asymptotic normality for the urn models can be obtained only when the condition
λ ≤ 1/2 is satisfied. This is a very strict condition. Even in the case of K = 3, it
is hard to be satisfied and to check it is not a easy work. Also, when λ is close
or exceeds 1/2, the variability of an urn model is extremely high. Ivanova (2003)
proposed a drop-the-loser (DL) rule which has the same limiting proportion as Wei
(1979)’s rule (See Example 4.1) but has much smaller variability. Consider an urn
containing balls of K + 1 types, type 0, 1, . . .K, when comparing K treatments. A
ball is drawn at random. If it is type k, k = 1, . . . , K, the corresponding treatment is
assigned and the subject’s response is observed. If the response is a success, the ball is
replaced and the urn remains unchanged. If a failure, the ball is not replaced. When
a type 0 ball is drawn, no subject is treated, and the ball is return to the urn together
with one ball of each type k, k = 1, . . . , K. Ivanova (2003, 2006) established the
asymptotic normality after embedding the urn process to a death-and-immigration
process. Here we give the strong approximation.
Theorem 5.1 There is a K-dimensional standard Brownian motion W (t) such that
Nn − nv =W (n)diag
(√v1p1
q1
, . . . ,
√
vKpK
qK
)
(I − 1′v) + o(n1/2−κ) a.s.,
for some κ > 0, where vk = (1/qk)/
∑k
j=1(1/qj), k = 1, . . . , K. Hence
√
n(Nn/n− v) D→ N
(
0, (I − v1′)diag(v1p1
q1
, . . . ,
vKpK
qK
)
(I − 1′v)
)
.
In particular, in the two-treatment case,
√
n(Nn/n − v) D→ N(0, σ2DL) with σ2DL =
q1q2(p1 + p2)/(q1 + q2)
3, the same as the σ2PW . For the generalizations of the DL rule
and their applications, one can refer to Zhang, Chan, Cheung and Hu (2007), Sun,
Cheung and Zhang (2007).
Proof of the theorem. Let Zm = (Zm,0, . . . , Zm,K) be the urn compositions after
the m-the assignment. And let µm be the number of draws of type 0 balls between
the (m − 1)-th assigment and the m-th assignment. Remember that when a type 0
ball is drawn, we add one ball of each treatment type, and when a treatment type
ball is drawn, it is replaced only when the response is a success. So
Zm,k − Zm−1,k = µm +Xm,k(ξm,k − 1) = µm −Xm,kqk +Xm,k(ξm,k − pk),
where ξm,k = 1 if the response of the m-th subject on treatment k is a success, and 0
if failure. Let Mn,k =
∑n
m=1Xm,k(ξm,k − pk),Mn = (Mn,1, . . . ,Mn,K), and Am be the
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sigma field generated by ξ1,k, · · · , ξm,k, k = 1, . . . , K, and X1, . . . ,Xm,Xm+1. Then
{Mn,Am} is a martingale. It follows that Zn,k − Z0,0 =
∑n
m=1 µm − Nn,kqk +Mm,k.
We can prove that Zn,k = o(n
1/2−δ0) a.s. for some δ0 > 0. For details of the proof,
we refer to Zhang, Hu, Chueng and Chan (2006b), Sun, Cheung and Zhang (2007).
Hence
Nn,k =
n∑
m=1
µm/qk +Mm,k/qk + o(n
1/2−δ0) a.s., k = 1, . . . , K,
which, together with the fact Nn,1 + · · ·+Nn,K = n, implies
Nn − nv =Mndiag(1/q1, . . . , 1/qK)(I − 1′v) + o(n1/2−δ0) a.s.
So, Nn − nv = O(
√
n log logn) a.s. by the LIL (Theorem B). On the other hand, for
the martingale {Mn} we have
n∑
m=1
E[(∆Mn)
′∆Mn|Fm−1] = diag(Nn,1p1q1, . . . , Nn,Kpkqk)
= n diag(v1p1q1, . . . , vKpkqk) +O(
√
n log log n) a.s.
By applying the strong approximation (Theorem E), we can define a K-dimensional
Brownian motion W (t) such that
Mn =W (n)diag(
√
v1p1q1, . . . ,
√
vKpkqk) + o(n
1/2−κ) a.s.
The proof is now completed. ✷
6 Doubly adaptive biased coin designs
The PW rule and urn model designs are a kind of design-driven adaptive designs,
which are constructed with intuitive motivation. However, clinical trials are usual
complex experiments on humans with multiple, often competing, objectives, includ-
ing maximizing power to detect clinically relevant differences in treatment outcomes,
maximizing the individual patient’s personal experience while treated in the trial, and
minimizing the total monetary cost of trial. These and other objectives can be defined
in terms of optimization of function of the trial’s parameters, the optimal allocation
proportion is often a function of unknown parameters. Take a binary response clinical
trail with two treatments 1 and 2 as an example. The well known Neyman proportion
is
ρ(p1, p2) =:
n1
n1 + n2
=
√
p1q1√
p1q1 +
√
p2q2
,
where pk (qk) is the probability of success (failure) of a trial treatment k, nk is the
number of subjects assigned to treatment k, k = 1, 2, The Neyman proportion maxi-
mizes the power of a test of the simple difference p1 − p2 for fixed sample size n. But
if we implement Neyman allocation, when p1+p2 > 1, we will assign more subjects to
the inferior treatment, which will compromise the ethical objective. Rosenberger, et al
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(2001) discussed another important optimization criteria that minimize the expected
number of treatment failures, n1q1+n2q2, for fixed the variance, p1q1/n1+p2q2/n2, of
the statistic p̂1 − p̂2 under an alternative hypothesis p1 6= p2. This leads the optimal
proportion as follows.
ρ(p1, p2) =
√
p1√
p1 +
√
p2
.
Many simulation studies have validated that a adaptive design with this proportion
as its target performs very satisfactorily for both the consideration of ethic and the
test of power. For other optimization criteria one can refer to Jennison and Turnbull
(2000) and Rosenberger, et al. (2001). Both Neyman allocation and the allocation of
Rosenberger,et al (2001) cannot be implemented directly in a clinical trail, because
we do not know the values of p1 and p2. In this section, we introduce an important
class of adaptive designs, doubly adaptive biased coin designs (DBCD), which is first
proposed by Eisele (1994) and Eisele and Woodroofe (1995), to target a pre-specified
allocation proportion.
Consider a clinical with K treatments. The outcome of a subject on treatment
k has a distribution fk(·|θk). Write θ = (θ1, . . . , θK). The pre-specified allocation
proportion is v = ρ(θ) = (ρ1(θ), . . . , ρm(θ)). Here ρ(y) is assumed to be continuous
function on the parameter space, taking the values on (0, 1)⊗k and twice differentiable
at the true value of the parameter θ. A multi-treatment DBCD proposed by Hu and
Zhang (2004a) is defined as follows.
To start, allocate M subjects to each treatment. At stage m, suppose m − 1(≥
MK) subjects are allocated and the outcomes, Nm−1,k outcomes of treatment k,
k = 1, . . . , K, are observed. Let θ̂m−1,k be the MLE of the parameter θk, k = 1, . . . , K.
Write θ̂m−1 = (θ̂m−1,1, · · · , θ̂m−1,K), and let ρ̂m−1 = ρ(θ̂m−1) be the current estimate
of the target allocation proportion. Now, the m-th subject is allocated to treatment
k with a probability:
Pm,k =: P(Xm,k = 1|Fm−1) = gk
(Nm−1
m− 1 , ρ̂m−1
)
, (6.1)
k = 1, . . . , K. Here g(x,y) = (g1(x,y), . . . , gK(x,y)) : (0, 1)
⊗2k → (0, 1)⊗k is the
allocation function. Write Pm = (Pm,1, . . . , Pm,K).
Theorem 6.1 Suppose the distributions f1(·|θ1), . . . , fK(·|θK) follow an exponential
family. Let g(x,y) be defined as
gk(x,y) =
yk
(
yk
xk
)γ
∑K
j=1 yj
(
yj
xj
)γ , k = 1, . . . , K; γ ≥ 0. (6.2)
Then
Nn − nv = O(
√
n log logn) a.s. and
√
n(Nn/n− v) D→ N(0,Σ),
where
Σ = Σρ +
1
1 + 2γ
(diag(v)− v′v +Σρ),
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Σρ =
(
∂ρ
∂θ
)′
diag
(
(v1I1(θ1))
−1, . . . , vKI1(θK))
−1) ∂ρ
∂θ
and Ik(θk) is the Fisher information function for a single observation on treatment k.
In particular, for the two-treatment case, suppose the targeted allocation proportion
of treatment 1 is ρ = ρ(θ1, θ2). Then
√
n
(
Nn,1/n− ρ
) D→ N(0, σ2DBCD) where
σ2DBCD = σ
2
ρ +
1
1 + 2γ
{
ρ(1− ρ) + σ2ρ
}
and σ2ρ =
(
I1(θ1)ρ
)−1
(∂ρ/∂θ1)
2 +
(
I2(θ2)(1− ρ)
)−1
(∂ρ/∂θ2)
2.
Example 6.1 Consider the binary response clinical trail with two treatments. For
the urn proportion ρ = q2/(q1 + q2),
σ2DBCD =
q1q2(p1 + p2)
(q1 + q2)3
+
2q1q2
(1 + 2γ)(q1 + q2)3
.
For the Neyman proportion ρ =
√
p1q1/(
√
p1q1 +
√
p2q2), σ
2
DBCD =
√
p1q1p2q2
(1+2γ)(
√
p1q1+
√
p2q2)2
+
1+γ
2(1+2γ)(
√
p1q1+
√
p2q2)3
(
p2q2(q1−p1)2√
p1q1
+ p1q1(q2−p2)
2
√
p2q2
)
.
For Rosenberger, et al’s proportion ρ =
√
p1/(
√
p1 +
√
p2), σ
2
DBCD =
√
p1p2
(1 + 2γ)(
√
p1 +
√
p2)2
+
1 + γ
2(1 + 2γ)(
√
p1 +
√
p2)3
(
p2q1√
p1
+
p1q2√
p2
)
.
From Theorem 6.1, we find that the asymptotic variability is a decreasing function
of parameter γ. However, the degree of randomness of the design decreases when γ
increases, because, as the value of γ becomes larger, the allocation probabilities shift
faster to extreme values 0 and 1 if there is a bias between the current sample allocation
and the estimated target. When γ =∞, the variability of the procedure is minimized,
but the procedure is completely predictable. The parameter γ can be chosen to reflect
the trade-off between the degree of randomness and the variability.
The allocation function defined in (6.2) is very special though it has fine properties.
For results for general allocation function g(·, ·), one can refer to Hu and Zhang
(2004a).
Proof the Theorem. Let ξm,k, m = 1, 2, . . ., be i.i.d. random variables, which
represent the outcomes on treatment k, k = 1, . . . , K. In clinical trial, only Xm,kξm,ks
are observed. Write ξm = (ξm,1, . . . , ξm,k). For simplifying the proof, we assume that
θk = Eξm,k is the mean of the outcomes, and so we use the sample mean as it estimate:
θ̂m,k =
∑m
i=1Xm,kξj,k
Nm,k
, k = 1, . . . , K.
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In practices, if necessary, we can add α > 0 in the numerator and β > 0 in the
denominator to avoid the nonsense case of 0/0, or to use prior information to estimate
the parameters. Assume E|ξm,k|2+δ < ∞ and write σ2k = Var{ξm,k}. Write Qm,k =∑m
i=1Xm,k(ξm,k − θk), then Qm,k is a martingale and θ̂m,k − θk = Qm,k/Nm,k. By the
LIL (Theorem B), we have
Qm,k = O(
√
n log logn) a.s. (6.3)
We first show the consistency of Nn/n. If let Am = σ(X1, . . . ,Xm+1, ξ1, . . . , ξm),
then
∑m
i=1 E[(Xi,k(ξi,k − θk))2|Ai−1] = σ2kNm,k. By Theorem A (b), it follows that
θ̂m,k → θk a.s. on the event {Nm,k →∞}. (6.4)
On the event {Nm,k < ∞}, θ̂m,k will fix to a value eventually. In either case, θ̂m,k
has a limit θ˜k in the parameter space, k = 1, · · · , K. By the continuity of ρ(·),
ρ̂m−1 → ρ(θ˜1, . . . , θ˜K) := v˜ ∈ (0, 1)⊗K a.s. Notice that the minimum of
∑
j yj(yj/xj)
γ
over
∑
j xj = 1 and xj ≥ 0 is
∑
j yj. It is easily seen that gk(x,y) ≤ yk(yk/xk)γ < yk
if xk > yk and
∑
j xj =
∑
j yj = 1. So, Pm,k ≤ ρ̂m−1,k if Nm−1,k/(m − 1) > ρ̂m−1,k.
DenoteMn,k =
∑n
m=1(Xm,k−E[Xm,k|Fm−1]). Let Sn = max{m ≥MK+1 : Nm−1,k ≤
(m− 1)ρ̂m−1,k} and max{∅} = MK. Then
Nn,k = NSn,k +
n∑
m=Sn+1
(Xm,k − E[Xm,k|Fm−1]) +
n∑
m=Sn+1
Pm,k
≤1 +NSn−1,k +Mn,k −MSn,k +
n−1∑
m=Sn
ρ̂m,k
≤1 +NMK−1,k + (Mn,k −MSn,k) + (Sn − 1)ρ̂Sn−1,k +
n−1∑
m=Sn
ρ̂m,k. (6.5)
Notice that |Mn,k −MSn,k| ≤ maxm≤n |Mm,k| = O(
√
n log log n) a.s. by the LIL, and
ρ̂m,k → v˜k. We conclude that lim supn→∞Nn,k/n ≤ v˜k a.s., k = 1, . . . , K. From the
fact that
∑n
k=1Nn,k/n =
∑n
k=1 v˜k = 1, we conclude that Nn,k/n → v˜k ∈ (0, 1) a.s.,
which implies that Nn,k →∞, k = 1, . . . , K. Hence θ˜k and θk (v˜ and v) must be iden-
tical by (6.4). We have proved the consistency of Nn/n. Further, according to (6.3),
we have θ̂m − θ = O
(√
log logm/
√
m
)
a.s., and then ρ̂m − v = O
(√
log logm/
√
m
)
a.s., which together with (6.5), yields
Nn,k − nvk ≤ O(
√
n log log n) +O(
√
Sn log log Sn)
+
n−1∑
m=Sn
O
(√
log logm/
√
m
)
= O(
√
n log log n) a.s.
By the fact that
∑n
k=1Nn,k/n =
∑n
k=1 v˜k = 1 again, we conclude that
Nn − nv = O(
√
n log logn) a.s. (6.6)
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Now, we begin the proof of the asymptotic normality. WriteMn = (Mn,1, . . . ,Mn,K)
and Qn = (Qn,1, . . . , Qn,K). Then by (6.3) and (6.6),
θ̂m,k − θk = Qm,k
mvk
+O
(
log logm
m
)
a.s.
It is easily seen that ∂g/∂x|x=y = −γ(I − 1′v) and ∂g/∂y|x=y = (γ + 1)(I − 1′v).
By the Taylor formula, we have
Pm − v = ρ
(Nm−1
m− 1 , ρ̂m−1
)− ρ(v, v)
=− γ(Nm−1
m− 1 − v
)
(I − 1′v) + (γ + 1)(θ̂m−1 − θ)∂ρ
∂θ
(I − 1′v)
+O
(∥∥Nm−1
m− 1 − v
∥∥2)+ (∥∥θ̂m−1 − θ∥∥2)
=− γ(Nm−1
m− 1 − v
)
+ (γ + 1)
(
θ̂m−1 − θ
)∂ρ
∂θ
+O
(
log logm
m
)
=− γ(Nm−1
m− 1 − v
)
+ (γ + 1)
Qm−1
(m− 1)diag(
1
v
)
∂ρ
∂θ
+O
(
log logm
m
)
=O
(√
log logm
m
)
.
Hence
Nn − nv =
n∑
m=1
(Xm − E[Xm|Fm−1]) +
n∑
m=1
(Pm − v)
=Mn − γ
n−1∑
m=1
Nm −mv
m
+ (γ + 1)
n−1∑
m=1
Qm
m
diag(
1
v
)
∂ρ
∂θ
+ o((logn)2) a.s.
On the other hand, it is easily checked that, for the martingale (Mn,Qn) we have
n∑
m=1
E[(∆Mm)
′(∆Mm)|Fm−1] =
n∑
m=1
(diag(Pm)− P ′mPm)
= n(diag(v)− v′v) +O(
√
n log logn) a.s.,
n∑
m=1
E[(∆Qm,k)
2|Fm−1] =
n∑
m=1
Pm,kσ
2
k = nvkσ
2
k +O(
√
n log log n) a.s.,
E[(∆Mm)
′(∆Qm)|Fm−1] = 0 and E[(∆Qm,kQm,j |Fm−1] = 0, k 6= j. So, by the
strong approximation (Theorem E), there are two independent K-dimensional stan-
dard Brownian motionsW (t) and B(t) such that for some κ > 0,Mn =W (n)Σ
1/2
1 +
o(n1/2−κ) a.s. and Qn,k = Bk(n)σk
√
vk + o(n
1/2−κ) a.s., k = 1, . . . , K, where Σ1 =
diag(v)− v′v. It follows that
Nn − nv =W (n)Σ1/21 − γ
n−1∑
m=1
Nm −mv
m
+ (γ + 1)
n−1∑
m=1
B(m)
m
Σ1/2
ρ
+ o(n1/2−κ) a.s.
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Hence, Nn − nv = G(n) + +o(n1/2−κ) a.s., where
G(t) = t−γ
∫ t
0
xγdW (x)Σ
1/2
1 + (γ + 1)t
−γ
∫ t
0
xγ−1B(x)dxΣ1/2
ρ
is the solution of the equation
G(t) =W (t)Σ
1/2
1 − γ
∫ t
0
G(x)
x
dx+ (γ + 1)
∫ t
0
B(x)
x
dxΣ1/2
ρ
.
It follows that
√
n(Nn/n− v) D→ N(0,Σ) with
Σ = Var{G(1)}
=Σ1
∫ 1
0
x2γdx+ (γ + 1)2Σρ
∫ 1
0
∫ 1
0
xγ−1yγ−1(x ∧ y)dxdy
=
1
2γ + 1
Σ1 +
2(γ + 1)
2γ + 1
Σρ.
The proof is now completed. ✷
7 Delayed responses
In practices, the outcomes in clinical trials are not available immediately prior to
the treatment allocation of the next subject. The estimating of the parameters, and
the updating of the urn when using urn models, can only be processed according to
observed responses. The effect of the delay of treatment results is fist studied in theory
by Bai, Hu and Rosenberger (2002) for the urn compositions in an urn model design
with discrete responses. After that, Hu and Zhang (2004b), Zhang, Chan, Chueng
and Hu (2007), Sun, Cheung and Zhang (2007) and Zhang, Hu, Chueng and Chan
(2006a) have shown that the delay machine does not effect the asymptotic properties
of the sample allocation proportions for many adaptive designs if the delay degree
decays with a power rate. The basic reason is that the total delayed responses is
a high order of square root of the sample size when the delay degree decays with a
power rate.
To describe the delay machine, we let tm be the entry time of the m-th subject,
where tm is an increasing sequence of random variables. Assume that {tm+1 − tm} is
a sequence of independent random variables. The response time of the m-th subject
on treatment k is denoted by rm(k). Suppose {rm(k);m ≥ 1} are sequence of inde-
pendent random variables, k = 1, . . . , K. Further, assume that {tm+1− tm, rm(k); k =
1, · · · , K,m ≥ n} is independent of the assignments X1, . . . ,Xn.
Assumption 7.1 Let δk(m, l) = I{rm(k) ≥ tm+l − tm} be an indicator function that
takes the value 1 if the outcome of the m-th subject on treatment k occurs after at
least another l subjects arrive, and 0 otherwise. Suppose for some constants C > 0
and γ ≥ 2,
µk(m, l) = P{δk(m,n) = 1} ≤ Cl−γ, m, l = 1, 2, . . . , k = 1, . . . , K.
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This assumption is easily satisfied. A practical approach is to assume that the entry
mechanism generates a Poisson process and the delay time has an exponential dis-
tribution in which both {rm(k)} and {tm+1 − tm} are sequences of i.i.d. exponential
random variables with means λk > 0 and λ0 > 0, respectively. This approach is
common in clinical studies and the probability µk(m, l) is
(
λk/(λ0 + λk)
)l
.
Let Sobsm,k (resp. N
obs
m,k) be the sum (resp. the number) of the outcomes on treatment
k observed prior to the (m+1)-th assignment, and Sm,k (resp. Nm,k) be the sum (resp.
the number) of all the outcomes of those being assigned to treatment k in the first m
subjects, k = 1, . . . , K.
Theorem 7.1 Suppose Assumptions 7.1 is satisfied, and the responses on each treat-
ment are i.i.d. random variables having finite (2 + δ)-th moments. Then for some
0 < δ0 <
1
2
− 1
2+δ
, we have
Rn,k =: Sm,k − Sobsm,k = o(n1/2−δ0) a.s. (7.1)
and Nn,k −Nobsn,k = o(n1/2−δ0) a.s., k = 1, . . . , K.
Proof. Let Ik(m, l) be the indicator function, which takes value 1 if the out-
come ξm,k on treatment k of the m-th subject occurs after the (m + l)-th assign-
ment and before the (m + l + 1)-th assignment, k = 1, . . . , K. For given m and l,
if Ik(m, l) = 1, we observe a response Xm,kξm,k. Hence, between the m-th assign-
ment and the (m + 1)-th assignment, the observed outcomes are Ik(m, 0)Xm,kξm,k,
Ik(m−1, 1)Xm−1,kξm−1,k, . . ., Ik(1, m−1)X1,kξ1,k, k = 1, . . . , K, and the sum of those
on treatment k is
∑m−1
l=0 Ik(m− l, l)Xm−l,kξm−l,k =
∑m
l=1 Ik(l, m− l)Xl,kξl,k. Hence,
Sobsm,k =
n∑
m=1
m∑
l=1
Ik(l, m− l)Xl,kξl,k =
n∑
m=1
n∑
j=m
Xm,kξm,kIk(m, j −m).
On the other hand, it is obvious that Sm,k =
∑n
m=1Xm,kξm,k =
∑n
m=1
∑∞
j=mXm,kξm,kIk(m, j−
m). It follows that
Rn,k =
n∑
m=1
∞∑
j=n+1
Xm,kξm,kIk(m, j −m).
Let 0 < φ < 1/2 be a number whose value will be specified later. Write ln = [n
φ].
Then
|Rn,k| =
∣∣∣( n∑
m=n−ln+1
+
n−ln∑
m=1
) ∞∑
j=n−m+1
Ik(m, j)Xm,kξm,k
∣∣∣
≤
n∑
m=n−ln+1
Xm,k|ξm,k|+
n∑
m=1
δk(m, lm)Xm,k|ξm,k|
≤Cnφ +
n∑
m=n−ln+1
(|ξm,k| − E[|ξm,k|])+ n∑
m=1
Xm,kE[δk(m, lm)|ξm,k|]
+
n∑
m=1
Xm,k
(
δk(m, lm)|ξm,k| − E[δk(m, lm)|ξm,k|]
)
. (7.2)
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For
∑n
m=1
(|ξm,k| − E[|ξm,k|]), due to Theorems 1.2.1 and 2.6.6 of Cso¨rgo˝ and Re´ve´sz
(1981),
n∑
m=n−ln+1
(|ξm,k| − E[|ξm,k|]) =O(√ln logn) + o(n 12+δ )
=o(nφ) + o(n
1
2+δ ) a.s.
For the martingale
∑n
m=1Xm,k
(
δk(m, lm)|ξm,k| − E[δk(m, lm)|ξm,k|]
)
, notice
E
(
Xm,k
(
δk(m, lm)|ξm,k| − E[δk(m, lm)|ξm,k|]
))2
≤E(δk(m, lm)|ξm,k|)2 ≤ (Eδk(m, lm)) δ2+δ (E|ξm,k|2+δ) 22+δ ≤ m− φγδ2+δ .
due to Assumptions 7.1 and the assumption of finite (2 + δ)-th moments. So, by the
LLN (Theorem A (a)),
∑n
m=1Xm,k
(
δk(m, lm)|ξm,k|−E[δk(m, lm)|ξm,k|]
)
= o(n
1
2
− φγδ
2(2+δ) logn)
a.s. Also
n∑
m=1
Xm,kE[δk(m, lm)|Dm,k|] ≤
n∑
m=1
(
Eδk(m, lm)
) 1+δ
2+δ
(
E|Dm,k|2+δ
) 1
2+δ
≤ C
n∑
m=1
m−
φγ(1+δ)
2+δ ≤ Cn1−φγ(1+δ)2+δ .
Combining the above arguments yields
Rn,k = O(n
φ) +O(n1−
φγ(1+δ)
2+δ ) + o(n
1
2+δ ) + o(n
1
2
− φγδ
2(2+δ) log n) a.s.
Choosing φ = 2+δ
1+(1+δ)γ
and 0 < δ0 < min{12 − φ, 12 − 12+δ , φγδ2(2+δ)} yields (7.1). The
proof of Nn,k −Nobsn,k = o(n1/2−δ0) a.s. is similar. ✷
8 Variability, power and asymptotic best adaptive
designs
The variability of the sample proportion Nn,k/n is an important quantity, which mea-
sures the distance between Nn,k/n and its limit vk. The smaller is the variability,
the smaller is the probability that there is large bias between Nn,k/n and vk. When
using a adaptive design with high variability, a clinical might result in assigning more
subjects to the inferior treatment making the allocation even less ethical than equal
allocation. Also, a trial with high variability might result in assigning only a few
subjects to one of the the treatments decreasing the efficiency in the test or the esti-
mation of parameters. According to (4.1), the asymptotic variability of the RPW rule
is very high unless both treatments have low success rates. It is extremely high when
q1 + q2 is close to 1/2, and it is showed that nVar{Nn,1/n} → ∞ when q1 + q2 < 1/2.
The RPW rule used in ECMO, 1985, trial assigned only one patient to the less suc-
cessful control therapy (see Royall, 1991, for discussion). The relationship among the
19
power, the target allocation and the variability of the designs is fist revealed by Hu
and Rosenberger (2003) in theory, though simulation studies had indicated there is
strong relationship among these quantities. Hu and Rosenberger (2003) proved that
the average power of a statistical test of the difference of distribution parameters is
a decreasing function of the variability of the designs. In Section 6, we have found
that the asymptotic variability of DBCD is a decreasing function of the parameter γ.
When γ →∞, the variability tends to its minimums
Σρ =
(
∂ρ
∂θ
)′
diag
(
(v1I1(θ1))
−1, . . . , vKI1(θK))
−1) ∂ρ
∂θ
.
Hu, Rosenberger and Zhang (2006) proved that this limit is the lower bound of the
asymptotic variability of adaptive designs among all adaptive designs which have the
same limiting proportion.
Assume the following regularity conditions:
1. The parameter space Θk is an open subset in R
d, j = 1, . . . , K;
2. The distributions of outcomes f1(·|θ1), . . ., fK(·|θK) follow an exponential fam-
ily;
3. For the limiting allocation proportion ρ(θ) = (ρ1(θ), . . . , ρK(θ) ∈ (0, 1)⊗K ,
Nn,j
n
→ ρj(θ) a.s. j = 1, . . . , K;
4. For a positive definite matrix V (θ),
√
n
(
Nn
n
− ρ(θ)
)
D→ N(0,V (θ).
Theorem 8.1 Under regularity conditions 1-4, there exists a Θ0 ⊂ Θ = Θ1 ⊗ · · · ⊗
ΘK with Lebesgue measure 0 such that for every θ ∈ Θ−Θ0,
V (θ) ≥
(
∂ρ(θ)
∂θ
)′
I−1(θ)
∂ρ(θ)
∂θ
:= ΣLB,
where I(θ) = diag
(
ρ1(θ)I1(θ1), . . . , ρK(θ)IK(θK)
)
and Ik(θk) is the Fisher informa-
tion for a single observation on treatment k = 1, . . . , K.
We refer to a adaptive design that attains the lower bound as asymptotic best for
that particular allocation ρ(θ). Table 1 gives the lower bounds of the asymptotic
variabilitites (σ2LB) for urn proportion (UP), Roenberger, et al’s proportion (RP)
and Neyman proportion (NP) in a binary response clinical trial for two-treatments.
It is interesting to note that the Zelen (1969)’s deterministic design (PW rule) is
asymptotic best among all procedures with limiting allocation proportion q2/(q1+q2),
the urn proportion. The RPW rule has the same limiting proportion, but it is not
asymptotic best because σ2RPW > σ
2
LB. The DL rule proposed by Ivanova (2003) is
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ρ σ2LB
UP q2
q1+q2
q1q2(p1+p2)
(q1+q2)3
RP
√
p1√
p1+
√
p2
1
4(
√
p1+
√
p2)3
(
p2q1√
p1
+ p1q2√
p2
)
NP
√
p1q1√
p1q1+
√
p2q2
1
4(
√
p1q1+
√
p2q2)3
(
p2q2(1−2p1)2√
p1q1
+ p1q1(1−2p2)
2
√
p2q2
)
Table 1: Lower bounds of the asymptotic variabilities for urn proportion, Rosenberger
et al’s proportion and Neyman proportion.
a random procedure having the same urn proportion and the asymptotic variability
σ2DL = q1q2(p1 + p2)/(q1 + q2)
3. So, the DL rule is asymptotic best. However, both
the RPW rule and the DL rule can only target this particular proportion, which is
not optimal in any formal sense, and can only be used for binary responses (c.f., Hu
and Rosenberger, 2003).
DBCD is also not asymptotic best (except γ =∞). But, it can target any desired
allocation and can be used for general responses, for example, continuous response.
Zhang, Hu and Cheung (2006) proposed an urn model, the SEU model, which can
target any pre-specified allocation proportion and can be used for general responses.
The drop-the-loser rule has also been generalized to GDL model, a kind of urn model
with immigration, by Zhang, Chan, Cheung and Hu (2007) and Sun, Chueng and
Zhang (2007), by using the estimators of unknown distribution parameters, such that
it can target any pre-specified allocation proportion and can be used for general re-
sponses. For a general pre-specified allocation proportion ρ = ρ(θ) in a K-treatment
trial, the asymptotic variance-covariance matrices of SEU, GDL and DBCD are given
in Table 2. Among these models, the DBCD can approach the lower bound for large
Model SEU GDL DBCD
Variability diag(ρ) − ρ′ρ+ 6ΣLB 2ΣLB diag(ρ)−ρ
′
ρ
1+2γ +
2+2γ
1+2γΣLB
Table 2: The asymptotic variability of SEU, GDL and DBCD for a same limiting
allocation
values of γ. However, the procedure becomes more deterministic as γ becomes larger,
and hence careful tuning of γ must be done to counter the trade-off between the ran-
domness and variability. The use of DBCD with γ = 2 was strongly recommended in
Hu and Rosenberer (2003) for binary response trials with two treatments, according
to the simulation study.
Very recently, we have found a fully randomized biased coin design (RBCD) for
two-treatment clinical trails, a kind of DBCD, which preserves randomization, attains
the lower bound, and can target any allocation. Whether or not an urn model can
be defined to have these properties is still an open problem. In the RBCD, instead of
using a continuous allocation function g(x, y), we use a discrete function: g(x, y) = αy
if x > y, y if x = y and 1 − α(1 − y) if x < y, where 0 < α < 1. That is, the m-th
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subject is allocated to treatment 1 with a probability
P(Xm,1 = 1|Fm−1) = Pm,1
=


αρ(θ̂m−1), if Nm−1,1/(m− 1) > ρ(θ̂m−1),
ρ(θ̂m−1), if Nm−1,1/(m− 1) = ρ(θ̂m−1),
1− α(1− ρ(θ̂m−1)), if Nm−1,1/(m− 1) < ρ(θ̂m−1).
When ρ(θ) ≡ 1/2, the RBCD is just the Efron (1971)’s biased coin design. The
following theorem gives the asymptotic results for the RBCD, the proof of which will
not be presented here.
Theorem 8.2 Suppose ρ(·, ·) is a continuous function on the parameter space and
twice differentiable at the true value of the parameter θ = (θ1, θ2), the distributions
f1(·|θ1) and f2(·|θ2) of the responses follow an exponential family. Then Nn,1/n −
ρ(θ) = O(
√
log logn/n) a.s. and
√
n (Nn,1/n− ρ(θ)) D→ N(0, σ2ρ), where
σ2ρ = (∂ρ(θ)/∂θ1)
2 (ρ(θ)I1(θ1))
−1 + (∂ρ(θ)/∂θ2)
2 ((1− ρ(θ))I2(θ2))−1.
Further, maxm≤n |Nm1 −mρ(θ) − σρW (m)| = o(
√
n) in probability, where W (t) is a
standard Brownian motion.
9 Discussion
In this paper, we have discussed several classes of adaptive designs. The play-the-
winner rule is the simplest procedure and has small variability. But is is too determin-
istic to be used in clinical trials. The randomized play-the-winner rule and urn models
are random procedures. But their variabilities are very high. Theoretical results, sim-
ulation studies and a real example in ECMO trial all indicate that the statistical test
in using a adaptive design with high variability is not powerful. However, besides in
adaptive designs, urn models have wide applications in many areas including biolog-
ical science, random algorithm and sampling, information science, etc. And the urn
models have strong relationship with multi-type branching processes. The study of
urn models has been of interest in a long history. The DL rule is randomized pro-
cedure and has the smallest variability among all the adaptive designs with limiting
allocation proportion q2/(q1 + q2). But it can only target this particular proportion
and can only be used for binary responses. When it is generalized to be able to tar-
get any pre-specified allocation, the variability is no longer the smallest (c.f. Table
2). Among the adaptive designs mentioned in this paper, the DBCD and RBCD are
the only procedures that preserves randomization, attains or can approach the lower
bound of the variability, can target any allocation and can be used for general discrete
or continuous responses.
The examples considered in this paper are binary response clinical trials. In prac-
tices, the responses of clinical trials appear in various types. For more examples and
discussion, we refer to a new book of Hu and Rosneberger (2006). In many clinical
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trials, covariate information is available that has a strong influence on the responses
of patients. For instance, the efficacy of a hypertensive drug is related to a patient’s
initial blood pressure and cholesterol level, whereas the effectiveness of a cancer treat-
ment may depend on whether the patient is a smoker or a non-smoker. The theory of
an adaptive design in using covariate information is much more complicated than those
without covarites. A limit success in deriving the asymptotic properties of covariate-
adjusted adaptive designs has been achieved by Zhang, Hu Cheung and Chan (2007).
The power study and evaluation of the covariate-adjusted adaptive designs are our
future studies. Also, in many clinical trials, the observed responses are usual survival
data. Though it has been shown that the delay of treatment results does not effect
the asymptotic properties in many adaptive designs, is is assume that the delayed
responses are finally observed if the time is long enough. It is an interesting topic of
studying the properties of the adaptive designs with missed or censored data.
Finally, in this paper, we only present the asymptotic results. It is important
to check the accuracy of the asymptotic approximations when using the theoretical
results to evaluate or compare designs. Simulations have indicated that in most cases
these designs closely approximate asymptotic results for a moderate sample size of
n = 100.
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